PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ingenol mebutate→

Ingenol Mebutate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
75567-37-2
PubChem CID
6918670
Molecular formula
C25H34O6
Molecular weight
430.5 g/mol
Drug class
Diterpene estertopical cytotoxic agent for actinic keratosis (withdrawn in EU)
Mechanism of action
Induces rapid cell death and inflammatory responses in treated epidermal cells. The precise molecular pathways are not fully defined; post-marketing evidence raised concerns about increased risk of skin malignancies.
Indications / reported uses
  • Historical topical indication: treatment of actinic keratosis in adults. The EU marketing authorisation for Picato was withdrawn in 2020 following concerns about skin malignancy risk; it should not be presented as a currently authorised EU treatment.

Sources: EMA — Picato referral and withdrawal decision · NLM MeSH — Ingenol mebutate · FDA product information

Identification source: PubChem record (CID 6918670). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ingenol Mebutate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ingenol Mebutate Permitted Daily Exposure (PDE) report (the Ingenol Mebutate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ingenol Mebutate Occupational Exposure Limit (OEL) report (the Ingenol Mebutate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.